Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News

SUDA Signs Additional Licence With Mitsubishi Tanabe

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader inoro-mucosal drug delivery, today announces that it has entered into an exclusive licenseagreement with Mitsubishi Tanabe Pharma Korea Ltd (MTPK), a wholly owned subsidiaryof Mitsubishi Tanabe Pharma Corporation (MTPC) (“Agreement”).

For more information, please download the attached PDF
Download this document